Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Great Tree Pharmacy CoROCO:6469 -1.49%71 Debt-to-Equity is 1.97 as of Jun. 2026, which is 3% above its 10-year median of 1.92. GuruFocus rates ROCO:6469 with a GF Score™ of 71/100 and a GF Value™ of NT$153.42 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 565 Healthcare Providers & Services companies, Great Tree Pharmacy Co ranks worse than 88.67% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Great Tree Pharmacy Co's Debt-to-Equity or its related term are showing as below:
ROCO:6469'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.19 Med: 1.92 Max: 2.34
Current: 1.97
During the past 13 years, the highest Debt-to-Equity Ratio of Great Tree Pharmacy Co was 2.34. The lowest was 0.19. And the median was 1.92.
ROCO:6469's Debt-to-Equity is ranked worse than 88.67% of 565
companies
in the Healthcare Providers & Services industry
Industry Median: 0.43
vs ROCO:6469: 1.97
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Great Tree Pharmacy Co Debt-to-Equity Related Terms
Great Tree Pharmacy Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Great Tree Pharmacy Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Tree Pharmacy Co Debt-to-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, Great Tree Pharmacy Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Great Tree Pharmacy Co Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Great Tree Pharmacy Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Great Tree Pharmacy Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Tree Pharmacy Co (ROCO:6469) has a Debt-to-Equity of 1.97 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Great Tree Pharmacy Co and its competitors. This is near median its historical median of 1.92. Over the past decade, Great Tree Pharmacy Co's Debt-to-Equity has ranged from 0.19 to 2.34. According to the industry distribution chart, Great Tree Pharmacy Co ranks #501 out of 565 companies in the Healthcare Providers & Services industry, placing it in the top 88.7%.
Is Great Tree Pharmacy Co's Debt-to-Equity too high?
Great Tree Pharmacy Co's current Debt-to-Equity of 1.97 is near median its 10-year median of 1.92. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 2.34. The Healthcare Providers & Services industry median Debt-to-Equity is 0.43. Great Tree Pharmacy Co's value of 1.97 is 358.1% above this industry median. Based on the distribution chart, Great Tree Pharmacy Co ranks #501 out of 565 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Great Tree Pharmacy Co has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Great Tree Pharmacy Co's Debt-to-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Great Tree Pharmacy Co ranks #501 out of 565 companies for Debt-to-Equity. This places Great Tree Pharmacy Co in the lower half of its industry. The industry median Debt-to-Equity is 0.43. Great Tree Pharmacy Co's value of 1.97 is 358.1% above this benchmark. Historically, Great Tree Pharmacy Co's own Debt-to-Equity has ranged from 0.19 to 2.34 over the past decade. While the company's 10-year median is 1.92 vs. the industry median of 0.43, Great Tree Pharmacy Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.43, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Great Tree Pharmacy Co's current Debt-to-Equity of 1.97 is 358.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Great Tree Pharmacy Co and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Great Tree Pharmacy Co's current Debt-to-Equity is 1.97, which is near median its own 10-year median of 1.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Tree Pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Great Tree Pharmacy Co (ROCO:6469) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$153.42, compared to a current price of NT$66.10 — trading 56.9% below its estimated fair value. The current Debt-to-Equity is 1.97, which is near median its 10-year median of 1.92 and 358.1% above the Healthcare Providers & Services industry median of 0.43. Great Tree Pharmacy Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Great Tree Pharmacy Co (ROCO:6469), the current Debt-to-Equity is 1.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Great Tree Pharmacy Co (ROCO:6469) Overvalued in 2026?
Based on GuruFocus' analysis, Great Tree Pharmacy Co stock appears to be undervalued.
The current stock price of NT$66.10 is trading 56.9% below its estimated GF Value™ of NT$153.42.
GuruFocus considers Great Tree Pharmacy Co to be Significantly Undervalued.
Key valuation signals for ROCO:6469:
Debt-to-Equity: 1.97 (near median its 10-year median of 1.92)
GF Value™: NT$153.42 vs. price of NT$66.10 (56.9% below fair value)
Industry Position: 358.1% above the Healthcare Providers & Services median (#501 of 565)
No single metric tells the full story. See the ROCO:6469 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Great Tree Pharmacy Co Ltd engages in management and trading of various drugs, health supplements, maternity and infant products, and cosmetics products. It also provides coordinated medicine procurement services to various clinics, outpatient centers, and medical communities. Besides, it is also an agency for domestic and foreign health care products sold in clinics, outpatient centers, and medical communities. Its products include infant formula, baby diapers, Maternal and Infant Related, Adult drinks, Nutrition and health care, Body care, Daily Necessities, medical equipment, and Pet products.
71GF Score
Get the complete analysis for ROCO:6469
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6469 has been successfully added to your 
